Sign inCreate account

Report workspace tools

NCT02075463TERMINATEDanonymous

A 16-week, Phase 2a, Single-arm, Multi-center, Open-label Study to Evaluate the Safety and Efficacy of GSK1278863 After Switching From Recombinant Human Erythropoietin (rhEPO), in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Chronically Hyporesponsive to rhEPO

Sponsor

Source record

GlaxoSmithKline

Phase

Source record

Phase 2a

Modality

AI-normalized

small molecule

Target

AI-normalized

Anemia in hemodialysis-dependent chronic kidney disease patients

Indication / condition

AI-normalized

Anemia

Intervention

Source record

GSK1278863, Placebo

Source & freshness

Source record

NCT ID

NCT02075463

Original source

ClinicalTrials.gov

Source last updated

Jun 21, 2017

Ingested at

May 31, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02075463

Title

A 16-week, Phase 2a, Single-arm, Multi-center, Open-label Study to Evaluate the Safety and Efficacy of GSK1278863 After Switching From Recombinant Human Erythropoietin (rhEPO), in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Chronically Hyporesponsive to rhEPO

Sponsor

GlaxoSmithKline

Status

TERMINATED

Phase

Phase 2a

Condition raw

Anemia

Condition normalized

Anemia

Modality raw

Anemia

Modality normalized

small molecule

Target raw

Anemia in hemodialysis-dependent chronic kidney disease patients

Target normalized

Anemia in hemodialysis-dependent chronic kidney disease patients

Interventions

GSK1278863, Placebo

Public preview

Source record

The clinical trial evaluated GSK1278863 for treating anemia in patients with chronic kidney disease who are hyporesponsive to rhEPO. The study aimed to assess the drug's safety and efficacy over a 16-week treatment period, following a 4-week run-in with rhEPO. The trial was sponsored by GlaxoSmithKline and included 15 participants, with a focus on optimizing hemoglobin levels.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A 16-week, Phase 2a, Single-arm, Multi-center, Open-label Study to Evaluate the Safety and Efficacy of GSK1278863 After Switching From Recombinant Human Erythropoietin (rhEPO), in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Chronically Hyporesponsive to rhEPO

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02075463

Status

TERMINATED

Phase

Phase 2a

Sponsor

GlaxoSmithKline

Executive brief

Investment-Ready Snapshot

The clinical trial evaluated GSK1278863 for treating anemia in patients with chronic kidney disease who are hyporesponsive to rhEPO. The study aimed to assess the drug's safety and efficacy over a 16-week treatment period, following a 4-week run-in with rhEPO. The trial was sponsored by GlaxoSmithKline and included 15 participants, with a focus on optimizing hemoglobin levels.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJun 21, 2017
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02075463

Indication

Anemia

Modality

small molecule

Target

Anemia in hemodialysis-dependent chronic kidney disease patients

Intervention

GSK1278863, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.